Matches in SemOpenAlex for { <https://semopenalex.org/work/W2201294382> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2201294382 abstract "Among the most innovative immunotherapies, autologous cellular immunotherapy aims at treating patients with their own immune cells that, before reinjection, have been educated ex vivo to fight disease. Antigen-specific regulatory T cells (Ag-Treg) are recognized as a promising tool for therapeutic intervention in patients with chronic inflammation and autoimmunity. Ovasave ® is an autologous ovalbumin-specific Treg (Ova-Treg) product that is in development for the treatment of severe Crohn's disease patients refractory to available treatments. Ovasave ® has shown a good tolerability and dose-related efficacy in a first-in-man open-labeled phase I/IIa study in refractory Crohn's disease patients. In this study, a 75% response rate and a 38% remission rate on the CDAI (Crohn's Disease Activity Index) were observed at the best dose. In addition, clinical response was correlated with a decrease in vitro proliferation of patient's white blood cells in response to ovalbumin, indicating that decreased proliferation to Ag-Treg specific antigen could be used as a biomarker of clinical response. A randomized controlled phase IIb clinical study with Ovasave will start mid-2014 to confirm the efficacy and tolerability of Ovasave ® in refractory's Crohn's disease patients. Ag-Treg manufacturing has been developed to be highly cost-effective and logistically simple: multiple years of treatment doses are manufactured by one processing from one blood sample. Ovasave ® is the lead product from TxCell's ASTrIA platform Ag-Treg products. From this platform, Col-Treg, an autologous collagen-II specific based product is in the final preclinical stage of development for the treatment of patients with autoimmune uveitis, an orphan chronic inflammatory condition of the eye, with a phase I/IIa clinical study planned for 2015. With Ovasave ® and Col-Treg as novel, personalized cellular immunotherapies for chronic autoimmune inflammatory diseases, Ag-Tregs represent a new therapeutic opportunity for patients who today have few or no treatment options." @default.
- W2201294382 created "2016-06-24" @default.
- W2201294382 creator A5023835265 @default.
- W2201294382 creator A5072226202 @default.
- W2201294382 date "2015-09-01" @default.
- W2201294382 modified "2023-09-30" @default.
- W2201294382 title "Cellular immunotherapy of chronic inflammation and autoimmunity using autologous antigen-specific T regulatory (Treg) cells" @default.
- W2201294382 doi "https://doi.org/10.1016/j.tracli.2015.06.211" @default.
- W2201294382 hasPublicationYear "2015" @default.
- W2201294382 type Work @default.
- W2201294382 sameAs 2201294382 @default.
- W2201294382 citedByCount "1" @default.
- W2201294382 countsByYear W22012943822020 @default.
- W2201294382 crossrefType "journal-article" @default.
- W2201294382 hasAuthorship W2201294382A5023835265 @default.
- W2201294382 hasAuthorship W2201294382A5072226202 @default.
- W2201294382 hasConcept C126322002 @default.
- W2201294382 hasConcept C147483822 @default.
- W2201294382 hasConcept C197934379 @default.
- W2201294382 hasConcept C203014093 @default.
- W2201294382 hasConcept C2776090121 @default.
- W2201294382 hasConcept C2777701055 @default.
- W2201294382 hasConcept C2778296632 @default.
- W2201294382 hasConcept C2778375690 @default.
- W2201294382 hasConcept C2780130043 @default.
- W2201294382 hasConcept C71924100 @default.
- W2201294382 hasConcept C79484868 @default.
- W2201294382 hasConcept C8891405 @default.
- W2201294382 hasConceptScore W2201294382C126322002 @default.
- W2201294382 hasConceptScore W2201294382C147483822 @default.
- W2201294382 hasConceptScore W2201294382C197934379 @default.
- W2201294382 hasConceptScore W2201294382C203014093 @default.
- W2201294382 hasConceptScore W2201294382C2776090121 @default.
- W2201294382 hasConceptScore W2201294382C2777701055 @default.
- W2201294382 hasConceptScore W2201294382C2778296632 @default.
- W2201294382 hasConceptScore W2201294382C2778375690 @default.
- W2201294382 hasConceptScore W2201294382C2780130043 @default.
- W2201294382 hasConceptScore W2201294382C71924100 @default.
- W2201294382 hasConceptScore W2201294382C79484868 @default.
- W2201294382 hasConceptScore W2201294382C8891405 @default.
- W2201294382 hasLocation W22012943821 @default.
- W2201294382 hasOpenAccess W2201294382 @default.
- W2201294382 hasPrimaryLocation W22012943821 @default.
- W2201294382 hasRelatedWork W1898522981 @default.
- W2201294382 hasRelatedWork W1974935765 @default.
- W2201294382 hasRelatedWork W1990396395 @default.
- W2201294382 hasRelatedWork W2004484891 @default.
- W2201294382 hasRelatedWork W2014138169 @default.
- W2201294382 hasRelatedWork W2070348986 @default.
- W2201294382 hasRelatedWork W2103001894 @default.
- W2201294382 hasRelatedWork W2153336606 @default.
- W2201294382 hasRelatedWork W2419543288 @default.
- W2201294382 hasRelatedWork W2441370914 @default.
- W2201294382 hasRelatedWork W2512614851 @default.
- W2201294382 hasRelatedWork W2523007325 @default.
- W2201294382 hasRelatedWork W2581740010 @default.
- W2201294382 hasRelatedWork W2894497500 @default.
- W2201294382 hasRelatedWork W2895164577 @default.
- W2201294382 hasRelatedWork W3097640690 @default.
- W2201294382 hasRelatedWork W3100964510 @default.
- W2201294382 hasRelatedWork W3147248871 @default.
- W2201294382 hasRelatedWork W3185262535 @default.
- W2201294382 hasRelatedWork W2006110046 @default.
- W2201294382 isParatext "false" @default.
- W2201294382 isRetracted "false" @default.
- W2201294382 magId "2201294382" @default.
- W2201294382 workType "article" @default.